The first anticancer immunotherapeutic agent was used T cell growth factor interleukin 2 (IL-2), where IL-2 treatment showed significant tumor suppression by enhancing T-cell activation in patients with metastatic kidney cancer and melanoma (3). Here, IL2 is linked to melanoma.